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A B S T R A C T
Background: Although remote ischemic preconditioning (RIPC) has emerged as an attractive strategy to
reduce cardiac injury in patients undergoing diverse cardiac surgical procedures, it is unclear whether
RIPC has protective effects in patients undergoing aortic valve replacement surgery without coronary
artery bypass grafting (CABG).
Methods: Hence, 100 adult patients undergoing elective aortic valve replacement for aortic valve
stenosis, without combined surgery with CABG, were prospectively randomly assigned in a 1:1 ratio to
either the RIPC group or the control group. The RIPC group underwent three cycles of 5-min inﬂation to
200 mmHg and 5-min deﬂation of an automated upper-arm cuff inﬂator after induction of anesthesia.
The control group had a deﬂated cuff placed on upper arm for 30 min. The primary endpoint was 72-h
area under curve (AUC) for troponin I (cTnI). Secondary endpoints were 72-h AUC for creatine kinase-MB
isoenzyme (CK-MB) release, incidence of acute kidney injury, extubation time, length of stay in intensive
care unit, and simpliﬁed acute physiology score (SAPS II).
Results: There were no signiﬁcant differences in cTnI AUC [195  190 arbitrary units (a.u.) in RIPC group
vs. 169  117 a.u. in the control group; p = 0.41] and CK-MB AUC between groups. None of the other
secondary endpoints differed between groups. Acute kidney injury occurred in 12 patients (24.5%) in the
control group and in 13 (26.0%) in the RIPC group (p = 0.86).
Conclusions: RIPC did not exhibit signiﬁcant cardiac or kidney protective effects in patients undergoing
aortic valve replacement surgery without CABG.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.Introduction
Cardiac surgery with cardiopulmonary bypass (CPB) induces
ischemia–reperfusion (I/R) injury to several organs. Postoperative
increase in troponins, creatine kinase-MB isoenzyme (CK-MB), or
serum creatinine levels has been associated with poor long-termDOI of commentary article: http://dx.doi.org/10.1016/j.jjcc.2015.07.006.
* Corresponding author at: Universite´ Angers, ‘‘Cardiopotection, Remodelage,
Thombose’’, EA 3860, rue Haute de Recule´e, FR-49045 Angers, France.
Tel.: +33 241 355 147; fax: +33 241 354 004.
E-mail address: faprunier@chu-angers.fr (F. Prunier).
http://dx.doi.org/10.1016/j.jjcc.2015.06.007
0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsoutcomes [1–4]. Remote ischemic preconditioning (RIPC) is a
powerful phenomenon whereby transient non-injurious I/R
episodes applied to an organ remote from the heart can protect
the myocardium from I/R injury [5–7]. The discovery that RIPC
stimulus can be induced non-invasively by simply inﬂating and
deﬂating a blood pressure cuff over systemic blood pressure has
facilitated its translation into the clinical setting. RIPC has emerged
as an attractive strategy to reduce myocardial injury and improve
outcome in patients undergoing cardiac surgery [6,8,9]. However,
it is unclear whether RIPC protects against myocardial injury in
patients undergoing isolated valvular surgery without associated
coronary artery bypass graft (CABG) surgery. In particular, therereserved.
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replacement (AVR), which is one of the most frequent cardiac
surgical procedures. Furthermore, conﬂicting data exist about
RIPC-induced kidney protection in the context of cardiac surgery
[8,10,11].
The Remote Ischemic Preconditioning in Aortic Valve Surgery
(RIPValve) trial was therefore designed to determine whether RIPC
would have cardiac and kidney protective effects in patients
undergoing AVR surgery without CABG.
Materials and methods
Study design
The RIPValve study was a prospective, randomized, single-
blinded (patients) controlled trial with blinded-endpoint analysis,
conducted at the University Hospital of Angers in France. Study
design, along with data collection and analysis, were all conducted
solely by the authors. The ethics committee of the University
Hospital of Angers approved the protocol, and the study was
conducted in accordance with the Helsinki Declaration and French
law. Written informed consent was provided by all participants
before being included in the study. The study was registered at
ClinicalTrials.gov (Identiﬁer: NCT01390129).
Funding
This work was supported by an academic grant from the
University Hospital of Angers.
Patients
From July 2011 to October 2012, we screened patients, aged
over 18 years and scheduled for elective AVR because of aortic
valve stenosis. Exclusion criteria were: combined surgery with
another valve or CABG, emergency surgery, coronary stenosis
>70%, left ventricular ejection fraction<35%, history ofmyocardial
infarction or percutaneous transluminal coronary angioplasty or
CABG, or preoperative treatment with nicorandil, or metformin, or
sulfonylurea within 8 days before surgery.
Experimental protocol
After induction of anesthesia, patients were randomly assigned
in a 1:1 ratio to either the RIPC group or the control group bymeans
of a computerized randomization table. Patients were stratiﬁed
according to their gender and to the identity of the surgeon who
performed the surgery. The RIPC group underwent three cycles of
5-min inﬂation to 200 mmHg and 5-min deﬂation of an automated
upper-arm cuff inﬂator (Spengler, Aix en Provence, France). The
control group had a deﬂated cuff placed on upper arm for 30 min.
The RIPC protocol began after anesthesia induction, and was
completed prior to the start of surgery.
Surgical procedure
Usual cardiac medications were given until the evening that
preceded surgery. Beta-adrenergic receptor antagonists were
given on the morning of surgery. Hydroxyzine (1 mg/kg) was
given orally at least 60 min before surgery. Propofol and sufentanil
infusions were started simultaneously with a computer-controlled
pump (Base Prime´a Fresenius Vial, Fresenius Kabi, France).
Propofol was started at predicted plasma concentration of 2–
3mg/l (pharmacokinetic model of Schnider) and increased every
3 min if necessary to obtain loss of consciousness. At that time,
atracurium besilate (0.5 mg/kg) was injected to facilitate trachealintubation. Sufentanil was started at effect compartment concen-
tration of 1 ng/ml (pharmacokinetic model of Gepts). From
tracheal intubation to skin closure, sufentanil concentration was
maintained between 0.6 and 1.2 ng/ml. After tracheal intubation,
propofol was stopped until the start of CPB, and anesthesia was
maintained with isoﬂurane (0.5–1.5%) or sevoﬂurane (0.5–2%). On
CPB, propofol target concentration was 1.2–1.6mg/ml. After CPB,
propofol was stopped and isoﬂurane or sevoﬂurane was used until
skin closure.
All patients underwent standardized aortic valve surgery and
cardiopulmonary bypass management. Brieﬂy, heparin was
administrated after full sternotomy to obtain an activated clotting
time longer than 350 s. The ascending aorta and the right atrium
were then cannulated. Surgical procedures were performed with
patients kept at normothermia (36–37 8C). After aortic cross-
clamping, antegrade cardioplegia was achieved using cold (20 8C)
4:1 blood-crystalloid solution directly in the ascending aorta and
possibly added by selective infusion in the coronary ostia in case of
signiﬁcant aortic regurgitation and/or extended aortic cross-
clamping. A temperature probe in the intraventricular septum
controlled efﬁcacy of infusion of the cardioplegia. After aortotomy,
AVR using usual stented aortic valve prostheses was then carried
out. De-airing of the heart was carefully done and veriﬁed by
transesophageal echocardiography. The heart was deﬁbrillated
after aortic unclamping if sinus rhythm did not restart spontane-
ously. Heparin activity was neutralized with protamine after
weaning from CPB. Intravenous dobutamine, norepinephrine, or
both were infused for hemodynamic support as required. All
patients were transferred to the intensive care unit (ICU) after
surgery. Tracheal extubation was performed when hemodynamic
conditionwas stable and the patient had adequate blood gas values
while breathing spontaneously. The durations of aortic clamping,
CPB, ventilation, and stay in ICU were recorded.
Biochemistry
Venous blood samples were drawn prior to intervention, and 6,
12, 24, 48, and 72 h after surgery for measurement of troponin I
(cTnI), CK-MB, and creatinine serum concentrations. We used a
chemiluminescent microparticle immuno assay (CMIA) to mea-
sure cTnI and CK-MB concentration (Architect i2000, Abbott
Diagnostics, Abbott Park, IL, USA). Creatinine levels weremeasured
with an enzymatic assay (Architect c16000, Abbott Diagnostics).
Estimated glomerular ﬁltration rate (GFR) was calculated by the
Modiﬁcation of Diet in Renal Disease formula [12].
Endpoints
The primary endpoint of the study was 72-h area under the
curve (AUC) for cTnI release, calculated according to the
trapezoidal rule. Secondary endpoints were 72-h AUC for CK-MB
release, incidence of acute kidney injury (AKI), extubation time,
length of stay (LOS) in ICU, and simpliﬁed acute physiology score
(SAPS II) [13]. AKIwas deﬁned according to the Acute Kidney Injury
Network criteria as an increase in serum creatine level by more
than 50% or more than 0.3 mg/dL from baseline within 72 h after
surgery [10,14].
Statistical analysis
Sample size calculation was based on the assumption that RIPC
would reduce troponin AUC by 30%. Drawing on experience in our
center in similar patients, 72-h troponin AUC valueswere expected
to be approximately 180  90 arbitrary units (a.u.). In order to have a
statistical power of 80% and two-sided alpha-level of 0.05, we
estimated the required sample size to be 45 patients in each group.
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until 50 qualiﬁed in each group.
Statistical analyses were performed using SPSS 15 (SPSS, Inc.,
Chicago, IL, USA). The Kolmogorov–Smirnov testwas used to assess
the distribution assumptions for normality. Given the normal
distribution of all continuous variables, they were expressed as
mean  standard deviation (SD). Categorical variables were given as
counts or absolute frequencies. Differences between groups were
assessed using chi-squared or Fisher’s exact test for categorical data,
with t-test applied for continuous data. All analyses were two-sided,
and statistical signiﬁcance was deﬁned as a p-value <0.05.
Results
Study population characteristics and operative data
A total of 147 patients were assessed for eligibility, with
47 patients excluded before randomization (Fig. 1). One patient
from the control group experienced an anaphylactic shock at the
induction of anesthesia and was therefore excluded from analysis.
Pre-operative characteristics of the study population were similar
in the randomized groups (Table 1). The time between the end of
the last inﬂation of the blood-pressure cuff and cross-clamping of
the aorta was 61  19 min (min = 33 min, max = 112 min). The time
from the induction of anesthesia to cross-clamping of the aorta was
not signiﬁcantly different between groups (103.4  17.4 min vs.
105.6  22.8 min, in the control group and RIPC group, respectively;
p = 0.60). There was no signiﬁcant difference with respect to CPB,[(Fig._1)TD$FIG]
Fig. 1. Flowchart of patientsaortic cross-clamp, and ventilation times between the two groups
(Table 2). Two patients from each group required reoperation for
bleeding.
Primary endpoint
As demonstrated in Fig. 2, the cTnI AUC was not signiﬁcantly
reduced in the RIPC group as compared to the control group
(195  190 a.u. vs. 169  117 a.u., respectively; p = 0.41).
Secondary endpoints
Similar to the cTnI release, the CK-MB AUCwas not signiﬁcantly
reduced in the RIPC group as compared to the control group
(797  539 a.u. vs. 795  488 a.u., respectively; p = 0.99).
Two patients from the control group required dialysis in the
postoperative period, and none in the RIPC group. However, serum
creatinine concentration was not signiﬁcantly different in both
groups at baseline and at each follow-up endpoint (data not
shown). GFRwas not signiﬁcantly different between both groups at
baseline and at 72-h follow-up (baseline values: 95  30 ml/min/
1.73 m2 in the control group and 90  24 ml/min/1.73 m2 in the RIPC
group, p = 0.30; 72-h values: 94  37 ml/min/1.73 m2 in the control
group and 86  36 ml/min/1.73 m2 in the RIPC group, p = 0.31).
Likewise, AKI occurred in 12 patients (24.5%) from the control group
and in 13 (26.0%) from the RIPC group (p = 0.86).
Finally, extubation time, length of stay in ICU, and SAPS II score
were similar in both groups (Table 2).in the RIPValve study.
Table 1
Characteristics of the study population.
Characteristics Control (n=49) RIPC (n=50) p-Value
Age, years 72.911.7 75.89.5 0.18
Sex (male/female) 24/25 27/23 0.62
Body mass index, kg/m2 28.25.1 29.26.4 0.40
Diabetes mellitus, n (%) 8 (16) 6 (12) 0.54
Dyslipidemia, n (%) 28 (57) 25 (50) 0.48
Hypertension, n (%) 40 (82) 37 (74) 0.36
Current smoking, n (%) 2 (4) 4 (8) 0.41
GFR, ml/min/1.73m2 95.229.7 89.623.9 0.30
COPD, n (%) 2 (4) 5 (10) 0.25
NYHA Class 2.1 0.6 2.3 0.6 0.18
LV ejection fraction, % 65.410.1 65.710.3 0.90
Logistic EuroSCORE 1 (%) 7.064.29 7.284.28 0.44
EuroSCORE 2 (%) 1.72 0.99 1.710.90 0.41
Medication at inclusion
Platelet inhibitors, n (%) 10 (20) 8 (16) 0.57
b-Blockers, n (%) 14 (29) 14 (28) 0.95
ACE-inhibitors or ARBs, n (%) 9 (18) 11 (22) 0.65
Statins, n (%) 21 (43) 19 (38) 0.62
Diuretics, n (%) 10 (20) 21 (42) 0.02
Calcium channel blockers, n (%) 7 (14) 9 (18) 0.62
Insulin, n (%) 0 0 –
Data are presented as mean SD or n (%).
RIPC, remote ischemic preconditioning; GFR, estimated glomerular ﬁltration rate;
COPD, chronic obstructive pulmonary disease; NYHA, New York Heart Association;
LV, left ventricular; ACE, angiotensin-converting enzyme; ARBs, angiotensin-II-
receptor blockers.
F. Pinaud et al. / Journal of Cardiology 67 (2016) 36–41 39Discussion
Elevated levels of cardiac biomarkers such as cTn I or T, and CK-
MB are associated with poor outcomes after open heart surgery
[1,3,15,16]. In a cohort of 267 consecutive patients undergoing
cardiac surgery, every nanogram per milliliter of cTnI increase was
associated with a 15% increase in the risk of postoperative
mortality [1]. Similarly, the development of AKI injury was
associated with higher mortality, and a higher risk for complica-
tions in patients undergoing cardiac surgery [17,18]. Evenminimal
changes in serum creatinine that occur in the postoperative periodTable 2
Operative and postoperative history of study patients.
Variable Control (n=49) RIPC (n=50) p-Value
Total CPB time, min 79.921.8 82.930.2 0.58
Aortic cross-clamp
time, min
55.318.8 59.525.2 0.35
Spontaneous
resuscitation,
n (%)
16 (32.6) 13 (23.0) 0.51
Ventilation time, h 6.43.6 6.44.1 0.97
Cumulative dose of
sufentanil, mg
30252 30766 0.74
Cumulative dose
of propofol, mg
545153 539172 0.86
Volume of
cardioplegic
solution, ml
1370374 1311394 0.44
Cumulative
drainage
volume, ml
346217 320179 0.51
Dialysis, n (%) 2 (4.1) 0 (0) 0.24
Reoperation for
bleeding, n (%)
2 (0.4) 2 (0.5) 1
SAPS II 29.89.8 30.46.5 0.73
ICU LOS, h 70.751.3 79.452.7 0.40
Data are presented as mean SD or n (%).
RIPC, remote ischemic preconditioning; CPB, cardiopulmonary bypass; ICU,
intensive care unit; LOS, length of stay; SAPS II, simpliﬁed acute physiology score.were associated with a substantial decrease in survival [2]. AKI
may occur in up to 30% of patients who undergo cardiac surgery,
with dialysis being required in approximately 1% of all patients
[19].
Several clinical trials have shown that RIPC reduced troponin or
CK release after surgical repair of congenital heart disease [20,21],
surgery for abdominal aortic aneurysm [22], and CABG with or
without concomitant valve replacement [9,23–25]. RIPC also
reduced renal injury after elective CABG [24,26]. Recently, RIPC
was associated with reduced secondary combined-endpoint
associating all-cause mortality and major adverse cardiac and
cerebrovascular events in patients undergoing elective CABG for
triple-vessel disease [9].
Although studies have reported renal or cardiac protective
effects in patients undergoing various cardiac surgeries (mainly
CABG), whether RIPC also reduced kidney andmyocardial injury in
patients undergoing heart valve surgery alone is still unclear. Xie
et al. reported that RIPC decreased cTnI release after heart valve
replacement alone [27]. In patients undergoing complex valvular
heart surgery, which was deﬁned as double-valve surgery,
combined valve and CABG, Bentall operation, combined mitral
valve surgery and tricuspid annuloplasty, or reoperation, Choi et al.
showed that RIPC did reduce CK-MB release whereas it did not
decrease kidney injury [10]. In the present RIPValve study, RIPC did
not reduce troponin and CK-MB release and did not impact on the
postoperative renal function in patients undergoing AVR alone.
Similarly, RIPC did not lead to signiﬁcant differences from controls
in some previous trials conducted in CABG surgery [28–[3_TD$DIFF] 0]. These
inconsistent ﬁndings may be attributed to a number of different
factors: (1) the timing, algorithm, and location (arm or leg) of the
RIPC stimulus [9]. For instance, Wu et al. reported that RIPC
decreased troponin release in patients undergoing mitral valve
surgery when the stimulus was applied to the right upper arm and
to the right upper leg whereas it was not protective when applied
to the right upper arm only [[4_TD$DIFF]31]; (2) The use of concomitant drugs
such as statins [[5_TD$DIFF]32], sulfonylurea antidiabetic drugs [ [6_TD$DIFF]33], and
anesthetics may impair cardioprotection [[7_TD$DIFF]34]. Fentanyl, propofol,
and inhaled anesthetics have been shown to be cardioprotective by
themselves, but it has been suggested that they may prevent
signiﬁcant RIPC-induced cardioprotection in cardiac surgery
[6]. However, ischemic and pharmacologic preconditioning inter-
actions remain unclear. They may antagonize each other rather
than act in synergy [30]. In a randomized prospective study,
Kottenberg et al. tested RIPC in patients undergoing CABG surgery
using either isoﬂurane or propofol anesthesia [[7_TD$DIFF]34]. RIPC during
isoﬂurane but not during propofol use decreased troponin release.
Even if propofol has been used in most of the negative studies, it is
noticeable that RIPC indeed induced cardioprotection in several
other studies in which patients received propofol [[8_TD$DIFF]23,25,35].
Because propofol has become a standard regimen in surgical
anesthesia in many centers, including our own, all patients
received propofol in the RIPValve study. Given the uncertainty
regarding the confounding inﬂuences of volatile anesthesia and
propofol administration, RIPC should be tested in the awake
patient before anesthesia and aortic valve surgery in future trials;
(3) Increased age [[9_TD$DIFF]36], gender [[10_TD$DIFF]37], and comorbidities frequently
associated with patients who need cardiac surgery such as left
ventricular hypertrophy, hypertension, and diabetes all impair
cardioprotection through altered survival signaling pathways
[[11_TD$DIFF]38]. As compared to the CABG surgery population in which
RIPC-induced cardioprotection has been frequently reported, it is
noteworthy that patients who undergo aortic valve surgery are
generally older, all with left ventricular hypertrophy, and are most
frequently female.
The reasons why well-conducted clinical trials provided
different results may also be solved by a better comprehension
[(Fig._2)TD$FIG]
p
p
Fig. 2. Myocardial injury assessed by 72-h troponin I (A, B) and creatine kinase-MB isoenzyme (C, D) release. AUC, area under the curve; CK-MB, creatine kinase-MB
isoenzyme; RIPC, remote ischemic preconditioning.
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intensive investigation, the underlying mechanisms continue to
elude us. A well-accepted theory holds that RIPC involves a neural
pathway to the remote organ and blood-borne factors, which
activate survival signaling pathways in the target organ [[12_TD$DIFF]39–
[13_TD$DIFF]41]. Several studies have described endogenous factors to be
involved in protective mechanisms, such as bradykinin [[14_TD$DIFF] 2],
opioids [[15_TD$DIFF]43], adenosine [[16_TD$DIFF]44], endocannabinoı¨ds [[17_TD$DIFF]45], erythropoie-
tin [[18_TD$DIFF]46], microvesicles [[19_TD$DIFF]47], apolipoprotein A-I [ [20_TD$DIFF]48,49], and
microRNA [[21_TD$DIFF]50]. One likely explanation is that RIPC activates the
release of several circulating humoral factors and involvesmultiple
endogenous protective mechanisms.
Study limitations
Because the RIPValve study was a single-center trial, the
negative result could be related to the surgical and anesthetic
practices in this center. However, this was theoretically an
advantage because all procedures were standardized in order to
homogenize procedures and drug use. Moreover, RIPC stimulus
was initiated in patients under anesthesia. Hence, further studies
are required to test RIPC in aortic valve surgery applied before
anesthesia and without propofol use.
In conclusion, RIPC did not exhibit signiﬁcant cardiac and
kidney protective effects in patients undergoing AVR surgery
without CABG in this prospective randomized trial.
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